Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006015 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00006015: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00006015 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006015, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying combination chemotherapy plus trastuzumab to see how well it works in treating patients with advanced, recurrent, or metastatic colorectal cancer.
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- BIOLOGICAL trastuzumab
- DRUG leucovorin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2000-05 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006015
The ClinicalTrials.gov registry entry for NCT00006015 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which oxaliplatin is the first listed.
NCT00006015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006015 about?
NCT00006015 is a clinical study titled "Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase...
What is the current status of trial NCT00006015?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2000-05. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00006015?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), trastuzumab (BIOLOGICAL), leucovorin calcium (DRUG).
Who is sponsoring clinical trial NCT00006015?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.